Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease
Huntington’s disease: Diabetes drug limits disease-related degeneration in mice Metformin, an existing drug for diabetes, shows promise in alleviating symptoms of early Huntington’s disease in mouse models. Huntington’s disease is a genetic disorder that results in the gradual deterioration of motor...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2019-06-01
|
| Series: | Experimental and Molecular Medicine |
| Online Access: | https://doi.org/10.1038/s12276-019-0264-9 |
| _version_ | 1828977705902669824 |
|---|---|
| author | Ana Sanchis María Adelaida García-Gimeno Antonio José Cañada-Martínez María Dolores Sequedo José María Millán Pascual Sanz Rafael P. Vázquez-Manrique |
| author_facet | Ana Sanchis María Adelaida García-Gimeno Antonio José Cañada-Martínez María Dolores Sequedo José María Millán Pascual Sanz Rafael P. Vázquez-Manrique |
| author_sort | Ana Sanchis |
| collection | DOAJ |
| description | Huntington’s disease: Diabetes drug limits disease-related degeneration in mice Metformin, an existing drug for diabetes, shows promise in alleviating symptoms of early Huntington’s disease in mouse models. Huntington’s disease is a genetic disorder that results in the gradual deterioration of motor skills and cognitive ability. It is caused by a defect in a single gene that then encodes a mutant huntingtin protein, which aggregates and kills brain cells. Growing observational evidence suggests that patients undergoing metformin treatment for diabetes type II exhibit fewer symptoms of age-related disease, as well as Huntington’s disease. Rafael Vázquez-Manrique at Hospital Universitario y Politécnico La Fe, València and Pascual Sanz at IBV-CSIC and CIBERER, València, and scientists across Spain used metformin to treat motor and neuropsychiatric symptoms in a Huntington’s mouse model. They found that metformin alleviated symptoms by actively reducing huntingtin levels, dispersing aggregations and limiting brain inflammation. |
| first_indexed | 2024-12-14T15:03:06Z |
| format | Article |
| id | doaj.art-9e189c31709a4e88a36088ef6c27365b |
| institution | Directory Open Access Journal |
| issn | 1226-3613 2092-6413 |
| language | English |
| last_indexed | 2024-12-14T15:03:06Z |
| publishDate | 2019-06-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Experimental and Molecular Medicine |
| spelling | doaj.art-9e189c31709a4e88a36088ef6c27365b2022-12-21T22:56:46ZengNature Publishing GroupExperimental and Molecular Medicine1226-36132092-64132019-06-0151611610.1038/s12276-019-0264-9Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington diseaseAna Sanchis0María Adelaida García-Gimeno1Antonio José Cañada-Martínez2María Dolores Sequedo3José María Millán4Pascual Sanz5Rafael P. Vázquez-Manrique6Research Group in Molecular, Cellular and Genomic Biomedicine, Health Research Institute La Fe (Hospital Universitario y Politécnico La Fe)Department of Biotechnology, Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural (ETSIAMN), Universitat Politécnica de ValènciaStatistics Unit, Health Research Institute La Fe (Hospital Universitario y Politécnico La Fe)Research Group in Molecular, Cellular and Genomic Biomedicine, Health Research Institute La Fe (Hospital Universitario y Politécnico La Fe)Research Group in Molecular, Cellular and Genomic Biomedicine, Health Research Institute La Fe (Hospital Universitario y Politécnico La Fe)CIBER de Enfermedades Raras (CIBERER)Research Group in Molecular, Cellular and Genomic Biomedicine, Health Research Institute La Fe (Hospital Universitario y Politécnico La Fe)Huntington’s disease: Diabetes drug limits disease-related degeneration in mice Metformin, an existing drug for diabetes, shows promise in alleviating symptoms of early Huntington’s disease in mouse models. Huntington’s disease is a genetic disorder that results in the gradual deterioration of motor skills and cognitive ability. It is caused by a defect in a single gene that then encodes a mutant huntingtin protein, which aggregates and kills brain cells. Growing observational evidence suggests that patients undergoing metformin treatment for diabetes type II exhibit fewer symptoms of age-related disease, as well as Huntington’s disease. Rafael Vázquez-Manrique at Hospital Universitario y Politécnico La Fe, València and Pascual Sanz at IBV-CSIC and CIBERER, València, and scientists across Spain used metformin to treat motor and neuropsychiatric symptoms in a Huntington’s mouse model. They found that metformin alleviated symptoms by actively reducing huntingtin levels, dispersing aggregations and limiting brain inflammation.https://doi.org/10.1038/s12276-019-0264-9 |
| spellingShingle | Ana Sanchis María Adelaida García-Gimeno Antonio José Cañada-Martínez María Dolores Sequedo José María Millán Pascual Sanz Rafael P. Vázquez-Manrique Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease Experimental and Molecular Medicine |
| title | Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease |
| title_full | Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease |
| title_fullStr | Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease |
| title_full_unstemmed | Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease |
| title_short | Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease |
| title_sort | metformin treatment reduces motor and neuropsychiatric phenotypes in the zq175 mouse model of huntington disease |
| url | https://doi.org/10.1038/s12276-019-0264-9 |
| work_keys_str_mv | AT anasanchis metformintreatmentreducesmotorandneuropsychiatricphenotypesinthezq175mousemodelofhuntingtondisease AT mariaadelaidagarciagimeno metformintreatmentreducesmotorandneuropsychiatricphenotypesinthezq175mousemodelofhuntingtondisease AT antoniojosecanadamartinez metformintreatmentreducesmotorandneuropsychiatricphenotypesinthezq175mousemodelofhuntingtondisease AT mariadoloressequedo metformintreatmentreducesmotorandneuropsychiatricphenotypesinthezq175mousemodelofhuntingtondisease AT josemariamillan metformintreatmentreducesmotorandneuropsychiatricphenotypesinthezq175mousemodelofhuntingtondisease AT pascualsanz metformintreatmentreducesmotorandneuropsychiatricphenotypesinthezq175mousemodelofhuntingtondisease AT rafaelpvazquezmanrique metformintreatmentreducesmotorandneuropsychiatricphenotypesinthezq175mousemodelofhuntingtondisease |